Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16732414 | 1.00 | KMT2A (0.55) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL3421333 | 1.00 | KMT2A (0.55) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL19720285 | 0.93 | KMT2A (0.50) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL13535467 | 0.93 | KMT2A (0.50) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL13535474 | 0.87 | KMT2A (0.44) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL31371076 | 0.87 | TSHR (0.48) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL4621117 | 0.86 | TSHR (0.56) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL5471268 | 0.84 | TSHR (0.54) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL13535468 | 0.83 | TSHR (0.48) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL12408480 | 0.82 | TSHR (0.52) | KMT2ATSHRCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598916-A | Antiviral compounds | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-115135383-B | Antiviral compounds | 吉利德科学公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-115135383-A | Antiviral compounds | 吉利德科学公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | KMT2A 1610/4885TSHR 4684/4885CA1 4883/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | KMT2A 1610/4885TSHR 4684/4885CA1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.